Stock Ratings / Health Care / ACXP / financials

ALZN (47) SKYE (36) XCUR (35) SCNX (42) ⌘ Pro Terminal →

Acurx Pharmaceuticals Inc. (ACXP) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

Q: Is ACXP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Acurx Pharmaceuticals Inc. (NASDAQ: ACXP) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $1.07 (0.00% 1D, market cap $5.9M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ACXP ranks #686 in composite RQD confidence.

Q: How does ACXP compare to ALZN and SKYE in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ACXP carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ALZN (Alzamend Neuro Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $5.9M) and SKYE (Skye Bioscience Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $5.8M). Among the 5-stock peer group, ACXP leads on earnings multiple (N/A) while ACXP leads on capital efficiency (-35.0% ROIC).

Q: What are the biggest fundamental strengths and SEC risk factors for ACXP?

Per ACXP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001736243), Acurx Pharmaceuticals Inc. generated $0 in revenue, -$8.0M in net income, and -$6.8M in free cash flow against $7.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Q: Where is ACXP trading relative to its 50-day, 200-day, and 52-week technical levels?

ACXP last traded at $1.07 (0.00% on volume of 64,578 shares), positioning the stock -17.69% below its 50-day simple moving average ($1.30) and -45.96% below its 200-day simple moving average ($1.98). Across its 52-week range of $1.03 to $7.54, ACXP sits at the 0.6% percentile with a 14-day RSI of 26.6 (OVERSOLD (<32)) and an implied next-earnings move of ±10.7% ($1.00 to $1.18).

Q: How profitable is Acurx Pharmaceuticals Inc. (ACXP)?

In FY 2025 (10-K), ACXP converted $4.0B of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

$1.07 0.00% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.07

Acurx Pharmaceuticals Inc. (ACXP) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (39/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $5.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.07 (-0.19%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (39/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.6% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-8.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ACXP)Realized 20D OHLCV Swing Band: ±10.7%

Deterministic 5-Pillar Attribution (39/100 Composite)

🔍 WHY ACXP SCORES 39/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (26% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (26% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 26.6 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$1.27-13.4% Next Q

Q2 (-2Q)

Grade D$1.10+2.7% Next Q

Q3 (-1Q)

Grade D$1.13-5.3% Next Q

Current

Grade D-$1.07-7.6% Hist 90D α

Trajectory: D (47) → D- (39)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ACXP Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ACXP currently carries a cautious 39/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.30) and Max Pain ($1.12) forces dealer call-delta covering toward $7.92.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ACXP• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ACXP Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 39%NO 61%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How ACXP Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $4.00B

FY24

Rev $4.00B

FY25

Rev $4.00B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$4.00B	52%	-0.2%	-$8.0M	-$6.8M	-45%
FY 2024	$4.00B	52%	-0.4%	-$14.1M	-$10.4M	-45%
FY 2023	$4.00B	52%	0%	-$14.6M	-$9.8M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ACXP)

✓Walkthrough of ACXP's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ACXP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -50.46%🛡️ HOLDING TREND SUPPORT

2026-10-30O $1.09H $1.10L $1.03C $1.07VOL 63.2K

RES: $1.45SUP: $0.97SMA50: $1.30SMA200: $1.98

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ACXP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ACXP Butterfly Map → + Track ACXP →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ACXP today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ACXP. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ACXP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ACXP)

Health Care Rank #686 of 1016 ⚔️ ALZN vs ACXP Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ACXP vs. ALZN, SKYE, XCUR, SCNX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Acurx Pharmaceuticals Inc. (ACXP) ranks #686 by composite RQD confidence (39/100, grade D-) and #929 by equity capitalization ($5.9M). Within this direct 5-issuer industry benchmark cohort, ACXP leads on earnings valuation at N/A trailing P/E, while ACXP leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. ALZN currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with ACXP at 39/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ACXP ACTIVE Acurx Pharmaceuticals Inc.	D-	39/100	—	—	-35.0%	0.00%	$5.9M	Benchmark Subject
ALZN Alzamend Neuro Inc.	D	47/100	—	—	-35.0%	+2.52%	$5.9M	/alzn-vs-acxp →
SKYE Skye Bioscience Inc.	D-	36/100	—	—	-35.0%	-13.82%	$5.8M	/skye-vs-acxp →
XCUR Exicure Inc.	D-	35/100	—	—	-35.0%	-8.04%	$6.1M	/xcur-vs-acxp →
SCNX Scienture Holdings Inc.	D-	42/100	—	76.8%	-35.0%	+2.65%	$5.7M	/scnx-vs-acxp →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001736243

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Acurx Pharmaceuticals Inc. (ACXP) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$8.0M, operating cash flow of -$6.8M, and free cash flow of -$6.8M (+34.6% YoY). On the balance sheet, ACXP closed FY2025 with $7.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$8.0M	-$6.8M	-$6.8M	$7.7M	—
FY2024 (FY)	2024-12-31	$0	-$14.1M	-$10.4M	-$10.4M	$3.9M	—
FY2023 (FY)	2023-12-31	$0	-$14.6M	-$9.8M	-$9.8M	—	—

3. ACXP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ACXP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Acurx Pharmaceuticals Inc. (NASDAQ: ACXP) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $1.07 (0.00% 1D, market cap $5.9M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ACXP ranks #686 in composite RQD confidence.

How does ACXP compare to ALZN and SKYE in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ACXP carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ALZN (Alzamend Neuro Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $5.9M) and SKYE (Skye Bioscience Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $5.8M). Among the 5-stock peer group, ACXP leads on earnings multiple (N/A) while ACXP leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ACXP?

Per ACXP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001736243), Acurx Pharmaceuticals Inc. generated $0 in revenue, -$8.0M in net income, and -$6.8M in free cash flow against $7.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ACXP trading relative to its 50-day, 200-day, and 52-week technical levels?

ACXP last traded at $1.07 (0.00% on volume of 64,578 shares), positioning the stock -17.69% below its 50-day simple moving average ($1.30) and -45.96% below its 200-day simple moving average ($1.98). Across its 52-week range of $1.03 to $7.54, ACXP sits at the 0.6% percentile with a 14-day RSI of 26.6 (OVERSOLD (<32)) and an implied next-earnings move of ±10.7% ($1.00 to $1.18).

ACXP Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Acurx Pharmaceuticals Inc. (ACXP)?

In FY 2025 (10-K), ACXP converted $4.0B of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: ACXP RQD Cockpit ACXP 12M Forecast ACXP Earnings & Move ACXP Dividends & DRIP ACXP Insiders & 13F ACXP Whale Options ACXP Profit Sankey ACXP News & Why